Research programme: cancer therapeutics - Corvus PharmaceuticalsAlternative Names: Adenosine production inhibitor; Humanised anti-CD73 monoclonal antibody; Interleukin-2 inducible kinase inhibitor; ITK Inhibitor; T Cell Reprogramming Drug; T-Cell Reprograming Drug
Latest Information Update: 02 Feb 2016
At a glance
- Originator Corvus Pharmaceuticals
- Class Antineoplastics; Monoclonal antibodies; Small molecules
- Mechanism of Action Emt protein-tyrosine kinase inhibitors; Nucleotidase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer